期刊文献+

抗抑郁药维持治疗与抑郁症临床痊愈 被引量:5

原文传递
导出
摘要 抑郁症是精神科的常见疾病,具有高患病率和高复发率的特点,给患者造成巨大痛苦,也给社会带来了重大的疾病负担。当前,人们已将临床痊愈作为抑郁症的治疗目标。临床痊愈意味着患者仅有极少抑郁症状且恢复了社会功能,通常以汉密尔顿抑郁量表17项评分≤7分或蒙哥马利.艾森贝格抑郁量表评分≤10分作为评价标准。尽管这一标准并非将症状完全消除才视为治愈,仅30%~40%的患者在单一抗抑郁药治疗后达到临床治愈。重要的是,获得临床缓解的患者停药后仍有50%以上的复发率。可见,如何获得和保持临床治愈是抑郁症治疗面临的一个难题。
作者 李惠春
出处 《中华精神科杂志》 CAS CSCD 北大核心 2012年第4期241-241,共1页 Chinese Journal of Psychiatry
  • 相关文献

参考文献6

  • 1Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry, 1992,49:769-773.
  • 2Geddes JR, Carney SM, Davies C,et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet,2003,361:653-661.
  • 3Frank E, Kupfer DJ, Perel JM, et al. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord,1993 ,27 :139-145.
  • 4Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med,2006, 119 (6 Suppl 1 ) : S3-10, discussion S62-70.
  • 5Solomon DA, Leon AC, Mueller TI, et al. Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry, 2005,66: 283 -290.
  • 6Rothschild AJ, Dunlop BW, Dunner DL, et al. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. Psychopharmacol Bull,2009,42:5-20.

同被引文献100

  • 1张明园主编.精神科评定量表手册.[M].第2版.长沙:湖南科技出版社,2004:128-130.
  • 2卡尔·R·罗杰斯主编.卡尔·罗杰斯论会心团体[M].北京:中国人民大学出版社,2006:135.
  • 3De Berardis D, Valchera A, Fornaro M, et al. Agomela- tine reversal of escitalopram-induced apathy: a case report [J]. Psychiatry Clin Neurosci, 2013,67 ( 3 ) : 190.
  • 4Carney RM, Shelton RC. Agomelatine for the treatment of major depressive disorder[J]. Expert Opin Pharmacoth- er,2011,12(15) :2 411.
  • 5Srinivasan V, Zakaria R, Othman Z, et al. Agomelatine in depressive disorders: its novel mechanisms of action [J]. J Neuropsychiatty Clin Neurosci, 2012,24 (3) : 290.
  • 6Courtet P, Olid E. Circadian dimension and severity of de- pression[J].Eur Neuropsychopharmacol, 2012, 22 (Suppl 3) : S476.
  • 7Lam RW. Onset, time course and trajectories of improve- ment with antidepressants[J]. Eur Neuropsychopharma- col, 2012,22 (Suppl 3) : S492.
  • 8Tiuvina NA, Smirnova VN. A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent de-pression and bipolar affective disorder[J]. Zh Nevrol Psikhiatr lm S S Korsakova , 2 012,112 ( 11 ) : 5 3.
  • 9Pizova NV.Valdoxan (agomelatine) in the treatment of de- pression in patients with cerebrovascular diseases: the re- suits of the Russian multicenter naturalistic study "Reso- nance" [J]. Zh Nevrol Psikhiatr Im S S Korsakova, 2012, 112(12):41.
  • 10Gorwood P, Bayle F, Vaiva G, et al. Is it worth assessing progress as early as week 2 to adapt antidepressive treat- ment strategy? Results from a study on agomelatine and a global meta-analysis[J]. Eur Psychiatry, 2013,28 (6):362.

引证文献5

二级引证文献281

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部